HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Agonists at the 2024 Annual Meeting of the American Society of Clinical Oncology
CAMBRIDGE, MA – April 30, 2024 – HiFiBiO Therapeutics, an innovative clinical stage biotechnology company committed to improving patient lives with single cell precision, today announced its participation in the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), set for May 31-June 4, 2024, in Chicago, IL. The company will present … Continued